TRCT
OLMA icon

Tower Research Capital (TRC)’s Olema Pharmaceuticals OLMA Stock Holding History

Tower Research Capital (TRC)’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90.2K Sell
6,052
-3,886
-39% -$86.5K ﹤0.01% 2265
2025
Q4 		$248K Buy
9,938
+7,413
+294% +$132K 0.01% 1270
2025
Q3 		$24.7K Sell
2,525
-5,479
-68% -$32.9K ﹤0.01% 3111
2025
Q2 		$34.1K Buy
8,004
+2,610
+48% +$11.6K ﹤0.01% 3306
2025
Q1 		$20.3K Sell
5,394
-17,320
-76% -$87.1K ﹤0.01% 2951
2024
Q4 		$132K Buy
22,714
+21,236
+1,437% +$212K ﹤0.01% 1991
2024
Q3 		$17.6K Sell
1,478
-7,722
-84% -$98.7K ﹤0.01% 3306
2024
Q2 		$99.5K Buy
9,200
+7,584
+469% +$82.2K ﹤0.01% 2583
2024
Q1 		$18.3K Sell
1,616
-8,906
-85% -$115K ﹤0.01% 3075
2023
Q4 		$148K Buy
10,522
+9,370
+813% +$126K ﹤0.01% 2332
2023
Q3 		$14.2K Sell
1,152
-20
-2% -$204 ﹤0.01% 3703
2023
Q2 		$10.6K Sell
1,172
-27,978
-96% -$169K ﹤0.01% 4099
2023
Q1 		$101K Buy
29,150
+19,358
+198% +$79K ﹤0.01% 1862
2022
Q4 		$24K Buy
9,792
+2,414
+33% +$7.04K ﹤0.01% 2966
2022
Q3 		$20K Sell
7,378
-748
-9% -$3.17K ﹤0.01% 3939
2022
Q2 		$33K Buy
8,126
+2,170
+36% +$6.88K ﹤0.01% 3280
2022
Q1 		$25K Sell
5,956
-915
-13% -$5.04K ﹤0.01% 3330
2021
Q4 		$64K Buy
6,871
+6,542
+1,988% +$136K ﹤0.01% 2571
2021
Q3 		$9K Sell
329
-900
-73% -$24.3K ﹤0.01% 4458
2021
Q2 		$34K Buy
1,229
+61
+5% +$1.74K ﹤0.01% 3353
2021
Q1 		$39K Buy
1,168
+598
+105% +$25.6K ﹤0.01% 3334
2020
Q4 		$27K Buy
+570
New +$26.7K ﹤0.01% 3663

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Tower Research Capital (TRC)'s OLMA Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Olema Pharmaceuticals (OLMA) stake by 39% in Q1 2026, selling an estimated $86.5K and leaving 6,052 shares worth $90.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2265.

Tower Research Capital (TRC) first reported a position in OLMA in Q4 2020 and has held it in 22 quarters since. The position peaked at $248K in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Tower Research Capital (TRC) held 6,052 shares of Olema Pharmaceuticals worth $90.2K as of Q1 2026.
  • Tower Research Capital (TRC) sold 3,886 Olema Pharmaceuticals shares in Q1 2026, an estimated $86.5K.
  • Olema Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2265 holding.
  • Tower Research Capital (TRC) first reported a position in Olema Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Tower Research Capital (TRC)'s Olema Pharmaceuticals position peaked at $248K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.